

CLINICAL AND BIOMEDICAL RESEARCH

Alexandre P. Zavascki

I am very pleased to introduce to researchers, medical and all healthcare-associated professionals, and to all readers potentially interested in the field, the first issue of the scientific journal Clinical and Biomedical Research (CBR). CBR is the former *Revista HCPA*, a 33 year-old scientific publication of *Hospital de Clínicas de Porto Alegre* and School of Medicine of *Universidade Federal do Rio Grande do Sul* that is now largely reformulated in order to reach a broader range of readers and researchers.

The aim of the CBR is becoming a high-quality scientific journal covering all fields of medicine, including clinical and experimental research, where worldwide researchers can publish their work and make it highly visible through the open access system. The invaluable efforts of the former Editors of *Revista HCPA*, who constructed a solid pathway, now allow us to look beyond our local horizons. Much work has been done in the latter year to concretize all topics necessary to provide CBR the status of an international journal. The name was modified, the editorial board now includes a higher number of external national and international members with distinguished academic qualifications, and submitted papers have been increasingly reviewed by peer-reviewers of international academic or scientific institutions.

CBR will publish original and review articles as well as case reports, images in medicine, and letters to the editor. We look forward to receive an increasing number of papers in English, the 'natural' idiom of science, but articles in Portuguese and Spanish will also be normally considered. Original papers are of extreme importance to the journal, reviews must be of interest for a broad range of readers, and case reports or images in medicine should present something new, unusual and/or of extreme relevance for those interested in the specific field. 'Vignette' reports that just illustrate a well-known topic will not be accepted. Letters are the vehicle to comment on an article published in the journal or to expose opinions regarding some medical or biomedical subject that may be relevant to many researchers or healthcare professionals.

All manuscripts, with the exception of letters, unless they present the results of an original research, will be peer reviewed. All efforts will be made to ensure a fair and reliable review process, which ultimately aims to increase the quality of papers published in the journal and guarantee that all published content has been analyzed by external peers, many of them, if not most, coming from international institutions. We will rely on the competence of these external experts and on our distinguished editorial board members to reach this objective.

We hope and will apply our best efforts to index CBR in the most important scientific databases. The running has begun. All papers published in this year will be evaluated by target databases. We also intend to offer efficient services to the contributors. CBR aims to provide the first decision within 6 weeks after

[Clin Biomed Res. 2014;34\(1\):3-4](#)

Department of Internal Medicine,
Medical School, Universidade Federal
do Rio Grande do Sul; Infectious
Diseases Service, Hospital de Clínicas
de Porto Alegre, Porto Alegre, Brazil.

Corresponding author:

Alexandre P. Zavascki
E-mail: azavascki@hcpa.ufrgs.br
Porto Alegre, RS, Brasil

submission. All papers are open access and free of article process charges, and our staff will also provide the divulgation of your work on social networks.

Finally, I would particularly like to thank all the editors and reviewers of *Revista HCPA*. As said above, their work has helped to build the way we are treading now. A special acknowledgement is made to all the colleagues that have contributed to *Revista HCPA*, now CBR. Professor Flávio Pereira Kapczinski and Professor Eduardo Pandolfi Passos deserve a specific mention for giving the start and support for the new directions of the journal.

I hope you appreciate the first issue of CBR and I am looking forward to see your research published in the journal.